|Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), MBA, GAICD||Chief Exec. Officer, Managing Director and Exec. Director||N/A||N/A||54|
|Mr. Nigel J. Baade B.Com, CPA, Grad. Dip. Arts||Chief Financial Officer and Company Sec.||N/A||N/A||N/A|
|Dr. A. Eglezos BSc(Hons),Ph.D., MBA||VP of Bus. Devel.||N/A||N/A||N/A|
|Dr. Jeremy R. Paull BSc (Hons), Ph.D.||VP of Devel. and Regulatory Affairs||N/A||N/A||N/A|
|Dr. David J. Owen BSc(Hons) Ph.D.||VP of Research||N/A||N/A||N/A|
Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications primarily in Australia. The company focuses on the development of VivaGel, an antimicrobial agent that is in Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for prevention of sexual transmitted infections. It also develops dendrimer-enhanced, or DEP versions of existing drugs, including DEP docetaxel, which is in Phase I clinical trial for breast, prostate, lung, and ovarian tumor; and agrochemicals. Starpharma Holdings Limited was founded in 1996 and is headquartered in Abbotsford, Australia.
Starpharma Holdings Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.